Synlogic Inc.

Synlogic Inc., a clinical-stage biotechnology company, is at the forefront of developing synthetic biotic medicines. These innovative therapeutics are designed using synthetic biology to address significant unmet medical needs. By engineering beneficial probiotic bacteria to perform specific metabolic functions in the human body, Synlogic aims to treat complex diseases where traditional pharmaceuticals may fall short. The company's unique approach has implications across various areas, such as genetic and metabolic disorders, immunological conditions, and even oncology. Synlogic Inc. collaborates with academic institutions and industry leaders to advance its research and development efforts. As a key player in the biotechnology sector, its work highlights the potential of synthetic biology in revolutionizing patient care and broadening treatment options for challenging medical conditions.